LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Aandelen Lijst・Ovid therapeutics Inc
Search

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.28 -5.39

Strong Buy

Prijsupdate 10 jun 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.27

Max

2.5

Belangrijke statistieken

By Trading Economics

Inkomsten

-27M

-17M

EPS

-0.125

Winstmarge

-2,366.017

Werknemers

23

EBITDA

-5.5M

-18M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+120.25% upside

Dividenden

By Dow Jones

Volgende Winsten

12 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-42M

440M

Vorige openingsprijs

7.67

Vorige sluitingsprijs

2.28

Nieuwssentiment

By Acuity

50%

50%

154 / 344 Rangschikking in Healthcare

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jun 2026, 23:36 UTC

Winsten

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Lezen

10 jun 2026, 23:19 UTC

Populaire aandelen

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Lezen

10 jun 2026, 23:09 UTC

Belangrijke Marktbewegers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Lezen

10 jun 2026, 23:04 UTC

Winsten

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Lezen

10 jun 2026, 20:44 UTC

Belangrijke Marktbewegers

Caterpillar Raises Quarterly Dividend 8%

DJ

Lezen

10 jun 2026, 23:49 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Should Take No Options Off The Table

DJ

Lezen

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Lezen

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Lezen

10 jun 2026, 23:47 UTC

Marktinformatie

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Lezen

10 jun 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Lezen

10 jun 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Lezen

10 jun 2026, 23:32 UTC

Marktinformatie

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Lezen

10 jun 2026, 23:20 UTC

Marktinformatie

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Lezen

10 jun 2026, 22:05 UTC

Marktinformatie

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Lezen

10 jun 2026, 21:57 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:52 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:35 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:22 UTC

Winsten

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:39 UTC

Marktinformatie
Winsten

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Lezen

10 jun 2026, 20:34 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 20:33 UTC

Winsten

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Lezen

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

120.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.33 USD  120.25%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

154 / 344 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat